Status:
COMPLETED
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
Lead Sponsor:
Institut Pasteur
Conditions:
SARS (Severe Acute Respiratory Syndrome)
COVID-19
Eligibility:
All Genders
5+ years
Brief Summary
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). Its complete genome was sequenced b...
Detailed Description
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO). This new virus is presented as the ...
Eligibility Criteria
Inclusion
- Affiliated with or benefiting from a Social Security system
- State of health compatible with a blood sample as defined in the protocol
Exclusion
- Person benefiting from a legal protection measure or unable to express informed consent to participation
- Have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (CORSER 1 and 2a, 2b)
- Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days prior to the date of the visit.(CORSER 1 and 2a, 2b)
Key Trial Info
Start Date :
March 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT04325646
Start Date
March 13 2020
End Date
May 31 2023
Last Update
July 7 2023
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens-Picardie
Amiens, France
2
EHPAD Villa Concorde
Asnières-sur-Seine, France
3
CHU François Mitterand
Dijon, France
4
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France